NEXGEL Triples Revenue with $5.5M Acquisition of Celularity’s Degenerative Disease Unit
Event summary
- NEXGEL acquires Celularity’s degenerative disease segment for $5.5M, led by Sequence LifeScience™.
- Deal expected to triple NEXGEL’s annual revenue to $35M and immediately boost profitability.
- Acquisition includes 6 established regenerative biomaterial products and 3 planned 510(k) filings.
- NEXGEL launches BioNX Surgical division to focus on advanced biomaterials for tendon repair and bone regeneration.
- Sequence LifeScience™ to serve as contract manufacturer and strategic partner for NEXGEL.
The big picture
NEXGEL’s acquisition of Celularity’s degenerative disease segment marks a strategic pivot into regenerative medicine, leveraging established products with existing reimbursement pathways. The deal, financed by Sequence LifeScience™, positions NEXGEL to accelerate growth and enhance margins in a competitive healthcare landscape. The formation of the BioNX Surgical division underscores NEXGEL’s commitment to expanding its commercial capabilities and product development pipeline.
What we're watching
- Revenue Integration
- How NEXGEL will integrate the acquired products into its existing portfolio and distribution channels.
- Regulatory Approvals
- The pace at which NEXGEL can secure 510(k) filings for the three new products planned for 2026, 2027, and 2028.
- Strategic Synergy
- Whether the partnership with Sequence LifeScience™ will drive meaningful growth and product innovation.
Related topics